



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

## Revision of Precautions Iguratumod

January 10, 2017

### **Non-proprietary name**

Iguratumod

### **Safety measure**

Precautions should be revised in the package insert.

In the Clinically Significant Adverse Reactions subsection regarding pancytopenia and leukopenia of the Adverse Reactions section, the following text should be revised (underlined parts are revised):

Pancytopenia, agranulocytosis, and leukopenia:

Pancytopenia, agranulocytosis, and leukopenia may occur. Patients should be carefully monitored through periodic testing, etc. If any abnormalities are observed, appropriate measures such as discontinuation of administration should be adopted.